ArticleJournal of cardiothoracic surgery2026
The predictive value and clinical application of measuring circulating endothelial progenitor cells in lung adenocarcinoma.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical utility of circulating tumor-derived endothelial cells in lung cancer detection and prognosis prediction.Oncology letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the potential of endothelial progenitor cells (EPCs) as biomarkers for lung adenocarcinoma.
methodsBlood samples were collected from 34 lung adenocarcinoma patients and 8 healthy controls at the Department of Tumor Immunology and Oncology. EPCs were quantified using flow cytometry, while serum VEGF levels were measured via enzyme-linked immunosorbent assays (ELISA). Comparative analyses between groups were performed, and correlations between EPC counts and VEGF levels were assessed. Bioinformatics analysis further explored VEGF expression in lung adenocarcinoma and its relationship with patient survival.
resultsPeripheral blood EPC counts were significantly elevated (7.36-fold higher) in treatment-naïve patients (n = 12) compared to healthy controls (n = 8) (p < 0.05). The chemotherapy group (n = 11) showed a further 1.05-fold increase compared to the treatment-naïve group (p < 0.05), while the chemotherapy+bevacizumab group (n = 11) demonstrated a 0.65-fold reduction compared to the chemotherapy group (p < 0.05). Serum VEGFA and VEGFB levels were significantly higher in patients than controls (0.08-fold and 0.11-fold increases, respectively; both p < 0.05). Positive correlations were observed between serum VEGFA/VEGFB levels and peripheral blood EPC counts (r = 0.593, p = 0.001; r = 0.440, p = 0.009, respectively). Bioinformatics analysis confirmed elevated VEGFA and VEGFB mRNA expression in lung adenocarcinoma patients compared to healthy individuals.
conclusionCirculating EPCs may serve as valuable biomarkers for lung adenocarcinoma diagnosis and prognosis. These findings provide a theoretical foundation for incorporating EPC assessment in early lung cancer screening and monitoring targeted therapy effectiveness in lung adenocarcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.